Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6FYI

X-ray Structure of CLK2-KD(130-496)/TG003 at 2.6A

Summary for 6FYI
Entry DOI10.2210/pdb6fyi/pdb
DescriptorDual specificity protein kinase CLK2, (1~{Z})-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one (3 entities in total)
Functional Keywordssplicing, phosphotransferase, transferase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight43637.51
Authors
Kallen, J. (deposition date: 2018-03-12, release date: 2018-07-18, Last modification date: 2024-01-17)
Primary citationKallen, J.,Bergsdorf, C.,Arnaud, B.,Bernhard, M.,Brichet, M.,Cobos-Correa, A.,Elhajouji, A.,Freuler, F.,Galimberti, I.,Guibourdenche, C.,Haenni, S.,Holzinger, S.,Hunziker, J.,Izaac, A.,Kaufmann, M.,Leder, L.,Martus, H.J.,von Matt, P.,Polyakov, V.,Roethlisberger, P.,Roma, G.,Stiefl, N.,Uteng, M.,Lerchner, A.
X-ray Structures and Feasibility Assessment of CLK2 Inhibitors for Phelan-McDermid Syndrome.
ChemMedChem, 13:1997-2007, 2018
Cited by
PubMed Abstract: CLK2 inhibition has been proposed as a potential mechanism to improve autism and neuronal functions in Phelan-McDermid syndrome (PMDS). Herein, the discovery of a very potent indazole CLK inhibitor series and the CLK2 X-ray structure of the most potent analogue are reported. This new indazole series was identified through a biochemical CLK2 Caliper assay screen with 30k compounds selected by an in silico approach. Novel high-resolution X-ray structures of all CLKs, including the first CLK4 X-ray structure, bound to known CLK2 inhibitor tool compounds (e.g., TG003, CX-4945), are also shown and yield insight into inhibitor selectivity in the CLK family. The efficacy of the new CLK2 inhibitors from the indazole series was demonstrated in the mouse brain slice assay, and potential safety concerns were investigated. Genotoxicity findings in the human lymphocyte micronucleus test (MNT) assay are shown by using two structurally different CLK inhibitors to reveal a major concern for pan-CLK inhibition in PMDS.
PubMed: 29985556
DOI: 10.1002/cmdc.201800344
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

227561

数据于2024-11-20公开中

PDB statisticsPDBj update infoContact PDBjnumon